John Leite's most recent trade in Veracyte Inc was a trade of 2,809 Common Stock done at an average price of $27.2 . Disclosure was reported to the exchange on June 4, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Veracyte Inc | John Leite | Chief Commercial Officer-CLIA | Sale of securities on an exchange or to another person at price $ 27.20 per share. | 04 Jun 2025 | 2,809 | 94,540 (0%) | 0% | 27.2 | 76,410 | Common Stock |
| Veracyte Inc | John Leite | Chief Commercial Officer-CLIA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.74 per share. | 02 Jun 2025 | 2,900 | 97,349 (0%) | 0% | 26.7 | 77,546 | Common Stock |
| Veracyte Inc | John Leite | Chief Commercial Officer-CLIA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 36,240 | 107,660 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | John Leite | Chief Commercial Officer-CLIA | Sale of securities on an exchange or to another person at price $ 31.96 per share. | 06 Mar 2025 | 5,011 | 100,249 (0%) | 0% | 32.0 | 160,146 | Common Stock |
| Veracyte Inc | John Leite | Chief Commercial Officer-CLIA | Sale of securities on an exchange or to another person at price $ 31.04 per share. | 06 Mar 2025 | 2,400 | 105,260 (0%) | 0% | 31.0 | 74,484 | Common Stock |
| Veracyte Inc | John Leite | Chief Commercial Officer-CLIA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 11,006 | 84,816 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | John Leite | Chief Commercial Officer-CLIA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.76 per share. | 27 Feb 2025 | 7,650 | 71,420 (0%) | 0% | 34.8 | 265,914 | Common Stock |
| Veracyte Inc | John Leite | Chief Commercial Officer-CLIA | Sale of securities on an exchange or to another person at price $ 33.84 per share. | 27 Feb 2025 | 5,746 | 79,070 (0%) | 0% | 33.8 | 194,445 | Common Stock |
| Veracyte Inc | John Leite | Chief Commercial Officer-CLIA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.12 per share. | 02 Dec 2024 | 1,314 | 74,860 (0%) | 0% | 44.1 | 57,974 | Common Stock |
| Veracyte Inc | John Leite | Chief Commercial Officer-CLIA | Sale of securities on an exchange or to another person at price $ 43.25 per share. | 02 Dec 2024 | 1,050 | 73,810 (0%) | 0% | 43.2 | 45,408 | Common Stock |
| Veracyte Inc | John Leite | Chief Commercial Officer-CLIA | Sale of securities on an exchange or to another person at price $ 29.78 per share. | 04 Sep 2024 | 5,479 | 76,174 (0%) | 0% | 29.8 | 163,159 | Common Stock |
| Veracyte Inc | John Leite | Chief Commercial Officer-CLIA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.55 per share. | 02 Sep 2024 | 1,315 | 81,653 (0%) | 0% | 31.5 | 41,488 | Common Stock |
| Veracyte Inc | John Leite | Chief Commercial Officer-CLIA | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 16 Jul 2024 | 1,277 | 82,968 (0%) | 0% | 25 | 31,925 | Common Stock |
| Veracyte Inc | John Leite | Chief Commercial Officer-CLIA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.75 per share. | 02 Jun 2024 | 1,314 | 84,245 (0%) | 0% | 20.8 | 27,266 | Common Stock |
| Veracyte Inc | John Leite | Chief Commercial Officer-CLIA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 49,880 | 85,559 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | John Leite | Chief Commercial Officer-CLIA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.00 per share. | 02 Mar 2024 | 3,008 | 35,679 (0%) | 0% | 24 | 72,192 | Common Stock |
| Veracyte Inc | Leite John | Chief Commercial Officer-CLIA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.54 per share. | 02 Dec 2023 | 556 | 38,687 (0%) | 0% | 26.5 | 14,756 | Common Stock |